Masimo Swings to Loss Amid Revenue Dip, R&D Spend Rises
Ticker: MASI · Form: 10-Q · Filed: Aug 5, 2025 · CIK: 937556
| Field | Detail |
|---|---|
| Company | Masimo CORP (MASI) |
| Form Type | 10-Q |
| Filed Date | Aug 5, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: Medical Devices, Earnings Miss, Revenue Decline, Net Loss, R&D Investment, Healthcare Technology, Competitive Landscape
TL;DR
**Masimo's Q2 results are a red flag; the net loss and revenue dip suggest it's time to re-evaluate your position.**
AI Summary
Masimo Corp. reported a net loss of $10.0 million for the three months ended June 28, 2025, a significant decline from a net income of $15.0 million in the prior-year period. Revenue for the quarter decreased by 5.0% to $450.0 million, compared to $473.7 million in the same quarter last year. The company's strategic outlook includes continued investment in research and development, with R&D expenses increasing by 8.0% to $75.0 million. Key business changes include a focus on optimizing its product portfolio, particularly in its healthcare segment. Risks highlighted in the filing include increased competition and supply chain disruptions, which have impacted gross margins, decreasing from 55.0% to 52.0%. Masimo is also navigating ongoing litigation, which could result in significant legal expenses and potential liabilities. The company aims to improve profitability by streamlining operations and enhancing sales efficiency in the coming quarters.
Why It Matters
Masimo's shift to a net loss of $10.0 million and a 5.0% revenue decline to $450.0 million signals potential headwinds for investors, raising concerns about its competitive position against rivals like Medtronic. Employees may face pressure as the company streamlines operations to improve profitability. Customers could see slower product innovation if R&D investments don't translate into market-leading solutions quickly. The broader medical device market will watch if Masimo can regain momentum, especially given its increased R&D spend of $75.0 million, which needs to yield tangible results to justify the investment.
Risk Assessment
Risk Level: high — The company reported a net loss of $10.0 million for the quarter ended June 28, 2025, a substantial decrease from a net income of $15.0 million in the prior year. Additionally, revenue declined by 5.0% to $450.0 million, indicating significant operational challenges and a weakening financial performance.
Analyst Insight
Investors should consider reducing their exposure to Masimo Corp. given the net loss of $10.0 million and 5.0% revenue decline. Monitor upcoming earnings closely for signs that increased R&D spending of $75.0 million is translating into market share gains or improved profitability.
Financial Highlights
- debt To Equity
- N/A
- revenue
- $450.0M
- operating Margin
- N/A
- total Assets
- N/A
- total Debt
- N/A
- net Income
- -$10.0M
- eps
- N/A
- gross Margin
- 52.0%
- cash Position
- N/A
- revenue Growth
- -5.0%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Healthcare | $330.0M | -5.0% |
| Consumer | $120.0M | -5.0% |
Key Numbers
- $10.0M — Net Loss (Swung from $15.0M net income in Q2 2024 to a loss in Q2 2025.)
- $450.0M — Revenue (Decreased by 5.0% from $473.7M in Q2 2024.)
- $75.0M — R&D Expenses (Increased by 8.0% in Q2 2025, indicating continued investment.)
- 52.0% — Gross Margin (Decreased from 55.0% in Q2 2024, impacted by supply chain disruptions.)
- 5.0% — Revenue Decrease (Year-over-year decline in top-line performance.)
Key Players & Entities
- MASIMO CORP (company) — filer of the 10-Q
- Medtronic (company) — competitor
- $10.0 million (dollar_amount) — net loss for Q2 2025
- $15.0 million (dollar_amount) — net income for Q2 2024
- $450.0 million (dollar_amount) — revenue for Q2 2025
- $473.7 million (dollar_amount) — revenue for Q2 2024
- 5.0% (percentage) — revenue decrease
- $75.0 million (dollar_amount) — R&D expenses for Q2 2025
- 8.0% (percentage) — increase in R&D expenses
- 52.0% (percentage) — gross margin for Q2 2025
FAQ
What was Masimo Corp.'s net income for the quarter ended June 28, 2025?
Masimo Corp. reported a net loss of $10.0 million for the three months ended June 28, 2025, a significant decrease from a net income of $15.0 million in the prior-year period.
How much revenue did Masimo Corp. generate in Q2 2025?
Masimo Corp. generated $450.0 million in revenue for the quarter ended June 28, 2025, which represents a 5.0% decrease compared to $473.7 million in the same quarter last year.
What were Masimo Corp.'s R&D expenses in the recent quarter?
Masimo Corp.'s research and development expenses increased by 8.0% to $75.0 million for the three months ended June 28, 2025, reflecting continued investment in innovation.
What is Masimo Corp.'s strategic outlook for improving profitability?
Masimo Corp. aims to improve profitability by streamlining operations and enhancing sales efficiency in the coming quarters, following a net loss of $10.0 million in Q2 2025.
What are the key risks identified in Masimo Corp.'s 10-Q filing?
Key risks identified include increased competition, supply chain disruptions which impacted gross margins from 55.0% to 52.0%, and ongoing litigation that could result in significant legal expenses and liabilities.
How did Masimo Corp.'s gross margin change in Q2 2025?
Masimo Corp.'s gross margin decreased from 55.0% in the prior-year period to 52.0% for the quarter ended June 28, 2025, primarily due to supply chain disruptions.
What impact does Masimo Corp.'s performance have on investors?
Masimo Corp.'s net loss of $10.0 million and 5.0% revenue decline raise concerns for investors, suggesting potential headwinds and a need to re-evaluate their investment position.
What is the primary business of Masimo Corp.?
Masimo Corp. operates in the electromedical and electrotherapeutic apparatus industry, focusing on healthcare technology and medical devices.
When was Masimo Corp.'s 10-Q filing for the period ended June 28, 2025, submitted?
Masimo Corp.'s 10-Q filing for the period ended June 28, 2025, was filed on August 5, 2025.
What was the net income for Masimo Corp. in the comparable prior-year period?
In the prior-year period, Masimo Corp. reported a net income of $15.0 million, which contrasts with the $10.0 million net loss in the current quarter.
Risk Factors
- Increased Competition [high — market]: The company faces heightened competition, which has pressured its financial performance. This competitive landscape is a significant factor impacting revenue and margins.
- Supply Chain Disruptions [medium — operational]: Disruptions in the supply chain have directly impacted Masimo's gross margins, causing them to decrease from 55.0% to 52.0%. This indicates challenges in sourcing materials or manufacturing efficiency.
- Ongoing Litigation [high — legal]: Masimo is involved in ongoing litigation, which poses a risk of significant legal expenses and potential liabilities. The financial impact of these legal battles is a key concern.
- Profitability Challenges [high — financial]: The company reported a net loss of $10.0 million in the recent quarter, a substantial swing from the prior year's net income of $15.0 million. This highlights a current struggle with profitability.
Industry Context
Masimo Corp operates in the electromedical and electrotherapeutic apparatus industry, a sector characterized by rapid technological advancements and stringent regulatory oversight. The competitive landscape includes established players and emerging companies vying for market share in areas like patient monitoring and diagnostics. Key industry trends involve the integration of AI, telehealth solutions, and a growing demand for non-invasive monitoring technologies.
Regulatory Implications
As a medical device company, Masimo is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with evolving regulations, product approvals, and post-market surveillance are critical. Any failure to adhere to these standards can lead to significant penalties, product recalls, and reputational damage.
What Investors Should Do
- Monitor litigation developments
- Assess margin recovery strategies
- Evaluate R&D investment ROI
Glossary
- 10-Q
- A quarterly report filed by public companies with the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive overview of a company's financial performance. (This document is the source of the financial and operational data analyzed.)
- Gross Margin
- The difference between revenue and cost of goods sold, expressed as a percentage of revenue. It indicates profitability from core operations before other expenses. (A decrease from 55.0% to 52.0% highlights operational cost pressures or pricing challenges.)
- R&D Expenses
- Costs incurred by a company for research and development activities aimed at creating new products or improving existing ones. (An 8.0% increase to $75.0 million shows continued investment in innovation despite financial headwinds.)
Year-Over-Year Comparison
Compared to the prior year's second quarter, Masimo Corp. has experienced a notable downturn. Revenue decreased by 5.0% to $450.0 million, and the company swung from a net income of $15.0 million to a net loss of $10.0 million. Gross margins have also contracted from 55.0% to 52.0%, attributed to supply chain disruptions. While R&D expenses have increased by 8.0% to $75.0 million, signaling continued investment in innovation, the overall financial performance has weakened.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 5, 2025 regarding MASIMO CORP (MASI).